Find Academic Supervisors

• Pharmacokinetics
• Pharmacodynamics
• Model-Informed Drug Development
• +4 more

Guohua An, MD, PhD, is an Associate Professor in the Department of Pharmaceutical Sciences and Experimental Therapeutics at the University of Iowa College of Pharmacy. She holds expertise in mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modeling, population PK in special populations, model-informed drug development, and quantitative systems pharmacology. Her research focuses on optimizing drug therapies for critically ill patients, infants, and surgical patients, with emphasis on antibiotics and novel drug candidates like HSD-1 inhibitors. Dr. An has a dual background in clinical pharmacy and pharmaceutical sciences, with industry experience at AbbVie and prior academic roles at the University of Florida. Education: MS in Clinical Pharmacology, Fudan University, China PhD in Pharmaceutical Sciences, SUNY University at Buffalo, USA Research Interests: Dr. An’s work integrates PK/PD modeling to inform drug development and clinical care, particularly in special populations. She explores mechanisms of drug disposition, target-mediated effects, and systems pharmacology to enhance therapeutic outcomes. Her recent studies address empiric dosing strategies for antibiotics (e.g., piperacillin-tazobactam), nonlinear pharmacokinetics of inhibitors, and quantitative models for incretin hormones. Publications: Her articles emphasize PK/PD modeling in antibiotics, HSD-1 inhibitors, and siRNA therapeutics. Key themes include population pharmacokinetics in cystic fibrosis patients, target-mediated drug disposition, and systems pharmacology approaches to diabetes therapies. Labs/Teams: Collaborates with interdisciplinary teams in clinical pharmacology and drug development, leveraging both academic and industrial partnerships.

Kimberly C. ClaeysView profile

Associate Professor

• Antimicrobial Stewardship
• Diagnostic Stewardship
• Implementation Science
• +4 more

Dr. Kimberly C. Claeys is an Associate Professor in the Department of Practice, Sciences, and Health Outcomes Research at the University of Maryland School of Pharmacy. She holds a PhD in Epidemiology from the University of Maryland School of Medicine, with a focus on diagnostic stewardship in healthcare-associated infections, particularly UTIs. Dr. Claeys is a Fellow of the Center for Innovation in Diagnosis and a 2022/23 Scholar in Diagnostic Excellence from the National Academy of Medicine. Her research emphasizes antimicrobial and diagnostic stewardship, implementation science for improving antibiotic use, and rapid diagnostic testing (RDT) for bacterial infections. She serves as Co-Chair for the University of Maryland Medical System (UMMS) Sepsis Program Rapid Diagnostic Subcommittee. Key areas of study include optimizing diagnostic testing workflows, reducing diagnostic errors, and aligning antibiotic therapy with diagnostic evidence. Her work bridges clinical practice and public health, addressing challenges in both acute care and long-term settings.

Mathangi GopalakrishnanView profile

Associate Professor

• Pharmacometrics
• Precision Therapeutics
• Predictive Analytics
• +9 more

Mathangi Gopalakrishnan, PhD, MPharm, is an Associate Professor in the Department of Practice, Science, and Health Outcomes Research at the University of Maryland School of Pharmacy. She is actively engaged in research, mentoring, and academic scholarship, with a focus on quantitative clinical pharmacology and data-driven therapeutic optimization. Education: PhD, Statistics, University of Maryland, Baltimore County MS, Statistics, University of Maryland, Baltimore County MPharm, Birla Institute of Technology & Science, Pilani, Rajasthan, India BPharmacy (Honors), Birla Institute of Technology & Science, Pilani, Rajasthan, India Her research interests center on pharmacometrics, precision therapeutics, predictive analytics, real-world data, and drug development . She integrates principles of clinical pharmacology, advanced frequentist and Bayesian statistical methods, and artificial intelligence/machine learning to enhance patient outcomes, particularly among vulnerable populations. Her lab's work includes designing prospective clinical pharmacokinetic trials for anti-epileptics and antimicrobials in patients on continuous renal replacement therapy, leveraging real-world data from electronic health records to optimize dosing in neonatal opioid withdrawal syndrome and pediatric anticoagulation, and developing models for disease progression in conditions like schizophrenia and binge-eating disorders. The trends in her recent publications reflect a consistent focus on model-informed precision dosing, real-world evidence generation, pharmacokinetic-pharmacodynamic (PK/PD) modeling in special populations, and methodological innovation in clinical trial design . Her work spans diverse therapeutic areas including critical care, neonatology, psychiatry, and maternal health, demonstrating a broad impact of quantitative pharmacology. Dr. Gopalakrishnan is accepting applications for postdoctoral positions in pharmacometrics at the Center for Translational Medicine, indicating active research funding and team leadership. Her collaborations extend to academic medical institutions nationwide, underscoring her role in multi-center research initiatives. She is involved in collaborative research with academic medical institutions across the country and has presented her work at major conferences including the Joint Statistical Meetings (JSM) and the American Conference on Pharmacometrics (ACoP).

• Pharmacokinetics
• Pharmacodynamics
• Population Pharmacokinetics
• +7 more

Leon Aarons is a Professor in the Manchester Pharmacy School at the University of Manchester, UK. He joined the institution in 1976 after a postdoctoral fellowship at the School of Chemistry, University of Leeds. His research focuses on pharmacokinetics, with specialties in population pharmacokinetics and pharmacodynamics (PK/PD), data analysis, and drug development. He collaborates widely in academia and industry, particularly in Europe, and contributes to initiatives like CAPKR (Computer Aided Pharmacokinetic Research) and the COST B25 management committee. Aarons holds editorial roles for journals including the Journal of Pharmacokinetics and Pharmacodynamics (European Editor) and British Journal of Clinical Pharmacology (Executive Editor). His work addresses variability in drug response across populations, with applications in malaria, pediatric care, anti-inflammatories, and oncology. He leads the Statistical Modelling Research Group and oversees collaborations with researchers like Kayode Ogungbenro and Hitesh Mistry. Education: PhD in Pharmacy (1973), University of Manchester MSc in Pharmacy (1971), University of Calgary BSc in Pharmacy (1968), University of Sydney Research Interests: Population PK/PD modeling using Maximum Likelihood and Bayesian techniques Optimal design for clinical trials and PK/PD studies Computer-aided trial design (CATD) via stochastic simulation Drug-drug interaction analysis in diverse patient populations Impact & Collaboration: Aarons' research contributes to UN Sustainable Development Goals, particularly in advancing drug development practices for precision dosing and addressing global health challenges. His work has influenced regulatory policies and industrial practices in pharmacokinetics. Labs & Teams: Active in the Statistical Modelling Research Group, CAPKR collaboration, and affiliated with the Digital Futures Institute and Christabel Pankhurst Institute at the University of Manchester.

Noriko DaneshtalabView profile

Associate Professor

• Cerebrovascular Dysfunction
• Stroke Pathophysiology
• Chronic Inflammation
• +12 more

Dr. Noriko Daneshtalab is an Associate Professor and Associate Dean of Graduate Studies and Research at Memorial University of Newfoundland, with a cross-appointment in the Faculty of Medicine. She is affiliated with the Department of Pharmacy and leads research in cerebrovascular dysfunction, stroke, and pharmacokinetics in inflammatory diseases. Education: B.Sc. in Pharmacology, University of Alberta (1998) Ph.D. in Pharmaceutical Sciences, University of Alberta (2005) Post-doctoral Fellowship, John P. Robarts Research Institute, London, Ontario (2004–2006) – Cell Biology Post-doctoral Fellowship, Memorial University of Newfoundland (2007–2010) – Cardiovascular Research Her research focuses on the mechanisms of cerebrovascular dysfunction associated with chronic inflammation, particularly in autoimmune diseases, and how this predisposes individuals to stroke. She investigates the pharmacokinetic and pharmacodynamic alterations of cardiovascular and immunomodulatory drugs in stroke development, especially in the context of arthritis models. Her work also explores the role of pro-inflammatory mediators like IL-17a in therapeutic failure of cardiovascular treatments and how disease severity and antihypertensive therapy affect cardiovascular outcomes in rheumatoid arthritis (RA) patients. The recent publications highlight her focus on cerebrovascular regulation in stroke-prone models, antihypertensive drug effects on cerebral blood flow, and novel biomaterials for drug delivery. These works span neuroscience, cardiovascular pharmacology, and pharmaceutical technology, emphasizing translational research from molecular mechanisms to therapeutic applications. Scientific Awards: Ignite Research Development Corporation (RDC) Fund Dr. Daneshtalab supervises graduate students and leads several research projects, including the development of a hypertensive-arthritic animal model and investigations into IL-17a signaling in cerebrovascular impairment. She has secured research funding, including the Ignite RDC grant, supporting innovation in her field. As Associate Dean, she plays a key role in advancing graduate research and scholarly development within the university. Her current projects are centered in experimental pharmacology and involve molecular signaling, animal modeling, and drug therapy evaluation, contributing significantly to understanding stroke in complex disease states.

William ZamboniView profile

Professor

• Cancer Pharmacology
• Nanomedicine
• Drug Delivery Systems
• +3 more

Dr. William Zamboni is a Professor at the UNC Eshelman School of Pharmacy and Director of the UNC Advanced Translational Pharmacology and Analytical Chemistry (ATPAC) Lab. His research focuses on translational pharmacology, optimizing anticancer therapies through pharmacokinetics, pharmacodynamics, and precision medicine. Key areas include nanoparticle drug delivery, overcoming tumor delivery barriers, and immune system interactions with nanomedicines. He collaborates with institutions like the UNC Lineberger Comprehensive Cancer Center and Carolina Institute of Nanomedicine. His lab specializes in analytical methods for drug quantification and preclinical/clinical studies of liposomal agents, antibodies, and ADCs. Research highlights include developing solid-phase separation (SPS) for nanoparticle analysis, evaluating mononuclear phagocyte system (MPS) biomarkers, and optimizing drug regimens for special populations (e.g., obesity, inflammatory diseases). The ATPAC Lab provides bioanalytical services, including LC-MS/MS assays and PK/PD modeling. Dr. Zamboni’s work emphasizes bridging preclinical findings to clinical applications, with a focus on enhancing anticancer drug efficacy and reducing toxicity.

Joseph RowerView profile

Academic

• Pharmacokinetics-Pharmacodynamics (PK-PD) Relationships
• Bioanalytical Methods Development
• Pediatric Clinical Pharmacology
• +7 more

Dr. Joseph Rower is a Research Assistant Professor in the Department of Pharmacology and Toxicology and Adjunct Assistant Professor in Pediatrics at the University of Utah's College of Pharmacy. He serves as Associate Director of the Center for Human Toxicology. Undergraduate: California Lutheran University, BS in Chemistry and Mathematics Doctoral: University of Colorado Anschutz Medical Campus, PhD in Pharmaceutical Sciences Postdoctoral Fellowships: Systems Biology at University of Colorado, Antiviral Pharmacology at University of Colorado, and Pediatric Clinical Pharmacology at University of Utah Dr. Rower's research focuses on pediatric pharmacology , particularly validating bioanalytical methods for small blood volumes to improve clinical care for children. His lab explores personalized dosing strategies , tacrolimus in pediatric transplantation , (val)ganciclovir for congenital cytomegalovirus , and cannabis pharmacokinetics in adolescents . Collaborative work spans preclinical models, clinical trials, and pharmacometric modeling. Recent publications emphasize pediatric pharmacokinetic-pharmacodynamic relationships , bioanalytical innovations , and personalized medicine applications in diverse areas including infectious disease , neurology , and critical care . Scientific Awards Board-certified clinical pharmacologist (Diplomate of the American Board of Clinical Pharmacology) Dr. Rower's lab within the Center for Human Toxicology integrates bioanalysis and pharmacometrics to identify patient-specific factors affecting drug pharmacokinetics. Collaborations include Dr. Albert Park (pediatric ENT), Dr. Chris Reilly's team (TRP channels and pulmonary toxicology), and international partners via the University of Utah's cores.

• Pharmacokinetics
• Pharmacodynamics
• Intravenous Anesthetics
• +3 more

Professor Mark Dershwitz is affiliated with the UMass Chan Medical School under the T.H. Chan School of Medicine , specifically the Department of Anesthesiology and Perioperative Medicine . He holds a PhD in Pharmacology (1982) and an MD (1982), both from Northwestern University , with postdoctoral training in anesthesiology at Massachusetts General Hospital (1984-88). His research focuses on the pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous anesthetics , particularly remifentanil and morphine . He pioneered studies on remifentanil’s esterase-mediated metabolism, demonstrating its consistent short duration even in patients with hepatic or renal failure . His work on postoperative nausea and vomiting (PONV) includes the first dose-response analysis of ondansetron and a safety reevaluation of droperidol , challenging its boxed warning. Recent articles highlight his expertise in anesthetic pharmacology , with trends in AI applications in medical education (e.g., ChatGPT-4 in board exams), opioid-PONV interactions , and clinical trial design involving human volunteers. His scientific awards include the 2017 Lamar Soutter Award for Excellence in Medical Education Multiple Outstanding Medical Educator Awards (2002-2016) 2001 Distinguished Alumnus Award from Oakland University

• Medication Management
• Kidney Disease
• Adverse Drug Reactions
• +4 more

Connie Van is a Senior Lecturer at the University of Sydney's School of Pharmacy, with expertise in medication management, chronic kidney disease, adverse drug reactions, and interprofessional collaboration. Her research bridges clinical practice and healthcare systems, with a focus on optimizing care for vulnerable populations such as pediatric cancer patients, dialysis patients, and critically injured children. Education: BPharm(Hons), PhD, Grad Cert Ed Stud (Higher Ed), Fellow of the Higher Education Academy (FHEA). Key research interests include: Medication safety and adverse drug reaction reporting Pharmacist-physician collaboration in primary care Sick day management protocols for chronic kidney disease Pediatric trauma psychosocial support Emergency nursing frameworks (e.g., HIRAID) Recent work emphasizes translational research, including a cluster-randomized trial for CKD screening and a pharmacy-led intervention study. Over 40 publications since 2007 reflect her multidisciplinary approach across nephrology, oncology, and emergency medicine. Notable grants include funding from the Department of Health and Aged Care for kidney disease quality initiatives, and multiple University of Sydney grants for projects like adverse drug reaction reporting tools and pharmacology education innovation. Current research student: Mimi Truong (project on sick day medication management in kidney disease).

• Infectious Diseases
• HIV/AIDS Research
• Antimicrobial Resistance
• +5 more

Dr. Steven Aronin is an Associate Clinical Professor of Medicine at Yale School of Medicine and serves as Chief of Infectious Disease at Waterbury Hospital. He holds multiple leadership roles including Medical Director of the Waterbury Hospital Infectious Disease and Travel Clinic, Program Director for Ryan White HIV Programs, and Hospital Epidemiologist. His academic work focuses on infectious diseases, particularly meningitis, endocarditis, HIV/AIDS, and antibiotic efficacy. Dr. Aronin completed his MD at Ross University School of Medicine and residency at Yale Primary Care Internal Medicine Program. He has been a Core Faculty member at Waterbury Hospital since 2009 and oversees the Yale-Waterbury Internal Medicine Residency Program's Infectious Disease training. He is also President of the Connecticut Infectious Disease Society. His research emphasizes translational antibiotic studies, particularly sulopenem's efficacy against resistant pathogens like E. coli and K. pneumoniae. Recent work includes phase 3 trials comparing sulopenem to ertapenem for intra-abdominal infections, and evaluating its use in UTIs and anthrax models. Key findings include sulopenem's superior efficacy in UTIs and its potential as a biodefense agent against inhalational anthrax. Dr. Aronin actively contributes to clinical guidelines through studies on HIV screening integration and bacteriuria's clinical impact. His work bridges academic research with direct patient care, emphasizing antibiotic stewardship and improving infectious disease treatment outcomes.

Zhiwei FengView profile

Assistant Professor

• Drug Discovery
• Computational Chemistry
• Machine Learning in Biology
• +6 more

Zhiwei Feng is an Assistant Professor at the School of Pharmacy, University of Pittsburgh , serving as Assistant Director of the Computational Chemical Genomics Screening Center (CCGS). He holds a PhD in Computational Chemistry/Materials from China and completed postdoctoral training at the University of Pittsburgh. With over 20 years of experience in drug discovery tools, his expertise includes computer-aided drug design (13 years), antibody drug discovery (6 years), and virtual reality apps for scientific visualization (7 years). Education: PhD in Computational Chemistry/Materials (2013), China MS and BS in Computer Sciences (2010 and 2007, respectively) Research Focus: AI-driven drug design (antibodies, small molecules) ML/DL-based chemogenomics platforms (e.g., Pain-CKB, Virus-CKB) Targeted therapies for pain, cancer, and stem cell expansion Systems pharmacology and PK/PD modeling His work emphasizes computational tools for drug repurposing, GPCR modulation, and anti-SARS-CoV-2 drug discovery. Key Achievements: Developed IsAb computational antibody design protocol Co-inventor of U.S. Patent 10,899,702 (TRPV1-based pain treatment) Over 65 publications in top journals like Cell , Nature Communications , and ACS Chemical Neuroscience . Lab & Collaborations: CCGS integrates computational and experimental methods for drug discovery Active collaborations in structural biology, systems pharmacology, and clinical data analysis

• Critical Care Pharmacotherapy
• Sepsis
• Acute Respiratory Distress Syndrome (ARDS)
• +3 more

Jeffrey P. Gonzales is an Associate Professor of Clinical & Administrative Sciences at Notre Dame of Maryland University’s School of Pharmacy. A dual-board-certified specialist in critical-care pharmacy and pharmacotherapy, he teaches within the Doctor of Pharmacy program and maintains an active program of clinical research, national presentations, and professional service. Education Doctor of Pharmacy – Idaho State University Pharmacy Practice Residency (PGY-1) – University of Nebraska Medical Center Critical Care Residency (PGY-2) – Detroit Receiving Hospital & University Health Center Critical Care Research Fellowship – University of Michigan College of Pharmacy Research & Scholarly Focus Dr. Gonzales’ work centers on optimizing pharmacotherapeutic outcomes in critically ill patients. His investigations span sepsis resuscitation, antimicrobial PK/PD, management of acute respiratory distress syndrome (ARDS), ICU delirium, and interprofessional education initiatives that bring pharmacy, nursing, and medical teams together to improve patient care. Recent Publication Themes Across the past 15 peer-reviewed articles (2015–2022), several themes emerge: rigorous evaluation of medication dosing in obesity and renal replacement therapy; quality-improvement analyses of order sets for diabetic ketoacidosis and antipsychotic discontinuation; and original pharmacokinetic studies of vancomycin, ceftolozane-tazobactam, and beta-lactams in sepsis. Collectively, these works advance evidence-based critical-care pharmacotherapy and inform national guidelines. Honors & Certifications Board Certified Critical Care Pharmacy (BCCCP), 2015–present Board Certified Pharmacotherapy Specialist (BCPS), 2002–2024 Presidential Citation, Society of Critical Care Medicine (2012, 2014, 2016–2023) Critical Care PRN Clinical Practitioner Award, ACCP (2016) Critical Care PRN Education Award, ACCP (2013) University of Maryland School of Pharmacy Faculty Preceptor of the Year (2010) Professional Service & Grants Dr. Gonzales is an active member of the American Association of Colleges of Pharmacy, the Society of Critical Care Medicine, and the American Society of Health-System Pharmacists. His leadership roles include directing interprofessional education grants that integrate sepsis simulation into pharmacy and nursing curricula, mentoring residents and fellows, and coordinating continuing-education symposia on critical-care pharmacotherapy. Laboratory & Collaborative Teams While he does not run a wet-lab, Dr. Gonzales collaborates with multidisciplinary critical-care teams at the University of Maryland Medical Center and other regional hospitals. These partnerships support prospective pharmacokinetic studies, quality-improvement initiatives, and translation of findings into bedside practice.

Raag AiranView profile

Assistant Professor

• Neuroimaging
• Neurointervention
• Ultrasound Techniques
• +3 more

Raag Airan is an Assistant Professor of Radiology (Neuroimaging and Neurointervention) and by courtesy, Materials Science and Engineering at Stanford University. His work bridges Noninvasive nervous system manipulation Ultrasound and nanoparticle engineering Theranostic applications Behavioral neuroscience His research focuses on Ultrasound-mediated drug delivery systems Neuroimaging of functional connectivity Neuromodulation for chronic pain and psychiatric disorders Glymphatic system modulation Recent publications highlight advancements in Acoustically activatable liposomes Sex-based pharmacological responses Algorithmic psychiatry frameworks Stem cell therapy imaging Deep learning-enhanced ultrasound

Diana S-L. ChowView profile

Professor

• Translational Drug Development
• Oncology
• Pharmacokinetics
• +3 more

Diana S-L. Chow is a Professor in the Department of Pharmacological and Pharmaceutical Sciences at the University of Houston College of Pharmacy . She also holds the Paula & John J. Lovoi Sr. Endowed Professor in Drug Discovery and Development and serves as Director of the Institute of Drug Education and Research . B.S. in Pharmacy, National Taiwan University, School of Pharmacy M.S. in Natural Product Chemistry, Ohio State University Ph.D. in Pharmaceutics, University of British Columbia Dr. Chow's research spans 40 years of translational drug development with a focus on anti-cancer therapies . She has pioneered formulations resulting in FDA-approved products like Busulfex® , with ongoing work on lung, pancreatic, and prostate cancer treatments. Her recent studies expand to underrepresented minority (URM) populations , pediatrics, and neurologically injured patients, emphasizing pharmacokinetics/pharmacodynamics (PK/PD) optimization. Her publications highlight expertise in analytical method development (e.g., LC-MS/MS assays), nanoparticle-based drug delivery , and neuroprotective agents . Key themes include preclinical-to-clinical translation , metabolite quantification , and bioavailability enhancement . 2023 Meritorious Achievement Award, UH College of Pharmacy 2023 Pharmaceutical Sciences Alumni Agent of Change, University of British Columbia 2016 Fellow, National Academy of Inventors 2009 Inventor of the Year, HIPLA Dr. Chow mentors extensively, with recognition as Outstanding Graduate Mentor (2022, 2021), and contributes to graduate education and research infrastructure through her directorship.

Fran AweekaView profile

Professor

• HIV Pharmacology
• Malaria Pharmacology
• Tuberculosis Pharmacology
• +6 more

Fran Aweeka is a Professor and Vice Chair of Research at the Department of Clinical Pharmacy, University of California San Francisco (UCSF) School of Pharmacy . She directs the Drug Research Unit (DRU) and serves as the Pharmacology Core Lead for the UCSF Center for AIDS Research . Her research focuses on pharmacokinetic and pharmacodynamic studies of HIV, malaria, and tuberculosis drugs, particularly in vulnerable populations in Africa and the U.S. She actively contributes to the PharmD degree program as a co-director of the Inquiry component and mentors students in pharmacology and international research. As a clinical pharmacologist with over 25 years of experience, Dr. Aweeka investigates drug interactions in co-infected patients, pharmacokinetics in pregnancy and pediatric populations, and mechanisms of HIV-associated inflammation. Her work includes PI roles on NIH R01 grants and leadership in global health initiatives like seasonal malaria chemoprevention studies in Uganda. The DRU under her direction provides advanced analytical techniques for drug quantification in plasma and target tissues, supporting over 30 NIH studies. Her recent research trends include pharmacokinetic-pharmacodynamic modeling of antimalarial and antiretroviral combinations, microvolume plasma assays , and drug exposure-response relationships in resource-limited settings. Publications from 2021–2025 reflect these areas, with emphasis on pregnancy pharmacokinetics , pediatric dosing , and global health pharmacology . Dr. Aweeka holds a PharmD from UCSF (1985) and a BS in Biological Sciences from USC (1981). She is a licensed pharmacist in California and has completed leadership programs like the Mentor Development Program . Her lab supports collaborative projects across national and international institutions, focusing on drug quantification in plasma, dried blood spots, and target cells.